Clinical trials
PDAC clinical trials
Below are recruiting pdac clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06639724RecruitingPhase 1
Test of fostamatinib with chemo before and after surgery for pancreatic cancer
This trial tests adding a new drug, fostamatinib, to standard chemotherapy before and after surgery for pancreatic cancer that can be removed. The goal is to see if the combination helps reduce the chance of cancer coming back.
La Jolla, CaliforniaAges 18 years+ - NCT06673017RecruitingPhase 1
Testing a new treatment for pancreatic cancer before surgery
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
Newport Beach, CaliforniaAges 18 years+ - NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Orlando, FloridaAges 18 years+ - NCT06895031RecruitingPhase 2
JYP0015 for advanced solid tumors with RAS mutations
This trial tests a new drug called JYP0015 for people with advanced solid tumors that have a specific change in the RAS gene. It aims to see if the drug can help when other treatments have stopped working or caused too many side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07030283RecruitingPhase 1
Chemotherapy in the belly for pancreatic cancer that has spread
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
Aurora, ColoradoAges 18 years+ - NCT07043270RecruitingPhase 2
Alternating chemo regimens for borderline resectable pancreatic cancer
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
Lebanon, New HampshireAges 18 years+ - NCT07049055RecruitingPhase 1/Phase 2
EDV nanocell therapy with chemo for advanced pancreatic cancer
This trial tests a new targeted therapy (EDV nanocells) combined with two standard chemotherapy drugs for people with metastatic pancreatic cancer. It is for patients whose cancer has progressed after first-line FOLFIRINOX or NALIRIFOX treatment.
El Segundo, CaliforniaAges 18 years+ - NCT07117045Recruiting
Low-dose CT scan for pancreatic cancer screening
This study uses artificial intelligence to analyze low-dose CT scans of the abdomen to detect early signs of pancreatic cancer. It may help find cancer before symptoms appear.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT07243262Recruiting
Breath test for pancreatic cancer detection
This trial tests whether a simple breath test can help detect pancreatic cancer earlier. If you have been referred for possible pancreatic cancer, you may be able to take part.
LondonAges 18 years+ - NCT07259590RecruitingPhase 1/Phase 2
GFH375 with cetuximab or chemo for KRAS G12D cancers
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07262957RecruitingPhase 4
Preventing complications after pancreatic surgery with a drug bundle
This trial tests whether giving a combination of three treatments—hydrocortisone (a steroid), octreotide (a drug that reduces digestive fluids), and a tissue patch—before and during pancreatic surgery can help prevent complications. It is for people with a very small pancreatic duct (3 mm or less) who are scheduled for pancreatic surgery.
AmsterdamAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT07542041Recruiting
Pancreatic Cancer Detection Using Advanced Tissue Analysis
This study tests a new way to analyze tiny samples of pancreatic tissue taken during a biopsy to better detect cancer. The method uses special technology to examine the physical properties of cells, which may help doctors diagnose pancreatic cancer more accurately.
Tampa, FloridaAges 18 years+ - NCT07554560Recruiting
Nutrition Support for Pancreatic Cancer Patients
This study tests a nutrition intervention for people with pancreatic cancer who are having trouble eating or absorbing nutrients. The goal is to help patients maintain strength and improve their quality of life during cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75 - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75
Hear when a new PDAC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pdac?
- Yes. Clin2 currently lists 97 recruiting pdac studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pdac trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pdac trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.